Efficacy and tolerability of vildagliptin as add‐on therapy to metformin in Chinese patients with type 2 diabetes mellitus

Pan, Changyu; Xing, Xiaoping; Han, Ping; Shao-xiong, Zheng; Ma, Jianhua; Liu, J.; Lv, Xiaoyi; Lu, Juming; Bader, Giovanni

doi:10.1111/j.1463-1326.2012.01593.x

Cited by 72 publications

(81 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The mean change from baseline in HbA1c after 24 weeks treatment with vildagliptin alone and vildagliptin with metformin was similar to that reported in various RCTs for vildagliptin [8][9][10] and vildagliptin +metformin. [13][14][15] These findings support the results from RCTs, where the magnitude of HbA1c reductions with vildagliptin 16 and vildagliptin+metformin was greater in patients with higher baseline HbA1c. 17 Approximately, 16.8% patients reached the HbA1c target value of ≤6.5% and 44.6% patients reached the HbA1c target value of ≤7% with vildagliptin as monotherapy suggesting a good glycemic control in 24 weeks.…”

Section: Discussionsupporting

confidence: 81%

Effectiveness, Safety and Tolerability of Vildagliptin with or without Metformin in Bangladeshi Patients with Type 2 Diabetes Mellitus: Results from Real-Life Observational Study

et al. 2016

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 81%

Effectiveness, Safety and Tolerability of Vildagliptin with or without Metformin in Bangladeshi Patients with Type 2 Diabetes Mellitus: Results from Real-Life Observational Study

et al. 2016

View full text Add to dashboard Cite

“…In the present study, the patients on metformin and vildagliptin combination showed a significant decline in , [9] who demonstrated significant decrease in FBS and PPBS levels, and Pan et al [10] who showed metformin and vildagliptin combination to significantly reduce fasting blood glucose (FBG) levels (P < 0.001) at 24 weeks when compared with metformin placebo.…”

Section: Discussionmentioning

confidence: 83%

“…Our results are in concurrence with Bosi et al, Pan et al, and Ved and Shah. [9,10,18] Bosi et al [9] evaluated the efficacy and safety of vildagliptin when added to metformin is well tolerated and produces clinically meaningful, dose-related decreases in A1C and FBS. Adverse events were reported by 65%.…”

Section: Discussionmentioning

confidence: 99%

Comparison of efficacy and safety of metformin and vildagliptin versus metformin and glimepiride in patients of Type 2 diabetes mellitus

Gullapalli¹,

Desai²

2017

Natl J Physiol Pharm Pharmacol

View full text Add to dashboard Cite

Background: Diabetes mellitus is a heterogeneous chronic metabolic disorder principally characterized by persistent hyperglycemia resulting from defects in insulin action and/or insulin secretion. In course of time, prolonged hyperglycemia and associated metabolic aberrations result in tissue toxicity manifested as accelerated atherosclerosis, renoretinal microangiopathy, and neuropathy leading to a variety of vascular, neurological, and focal complications. Aim and Objective: The aim of this study is to evaluate the efficacy and safety of metformin and vildagliptin versus metformin and glimepiride in patients with Type 2 diabetes mellitus. Materials and Methods: This is a longitudinal interventional study. A total of 60 patients were enrolled in the study. Those patients who were already on metformin 500 mg bid with poor glycemic control were included in the study. These 60 patients were divided into two groups each consisting of 30 patients. Group A patients received glimepiride 1 mg bid and metformin 500 mg bid. Group B patients received vildagliptin 50 mg bid and metformin 500 mg bid. The total period of the study was 3 months. Results: After 3 months of treatment, both the groups caused a significant decline in blood glucose levels both fasting blood sugar (FBS) as well as postprandial blood sugar (PPBS) levels. There was a significant difference between the two groups in reducing the FBS levels and PPBS. Hemoglobin A 1c (HbA1c) was also reduced significantly in both groups at 12 weeks. After 3 months of therapy, there was a reduction in HbA 1C in B group. The reduction of HbA 1C was not statistically significant between the two groups. Adverse effects were more with metformin and glimepiride group at the end of 3 months therapy. There was a significant difference in the incidence of adverse effects between both the groups. Conclusions: Vildagliptin and metformin combination provided better efficacy comparable to that of glimepiride and metformin combination and resulted in better adverse effect profile with lower risks of hypoglycemia and weight gain.

show abstract

“…Four abstracts that had been included in the previous analysis were replaced by full-text publications. In total,19 studies were included in the base case analysis at 24-weeks ± 6 weeks [7,23,[25][26][27][28][29][30][31][32][33][34][35][36][37][38][39][40][41] (Table S2) and a further 4 were eligible for the sensitivity analysis due to timeframe (± 8 weeks) and quality issues (Table S4). Of the 15 studies reporting data at the 52-week time point, 8 were included in the base case analysis [8,[42][43][44][45][46][47][48] (Table S3) with the remaining 7 assessed in the sensitivity analysis for the same reasons (timeframe and quality issues) (Table S4).…”

Section: Systematic Review Search Resultsmentioning

confidence: 99%

Systematic Review and Network Meta-analysis to Compare Dapagliflozin with other Diabetes Medications in Combination with Metformin for Adults with Type 2 Diabetes

Barnett

Me²,

Fenici³

et al. 2014

Intern Med

View full text Add to dashboard Cite

Objective: A network meta-analysis (NMA) update was undertaken to evaluate the sodium glucose cotransporter-2 (SGLT-2) inhibitor, dapagliflozin, versus other antidiabetes medications as add-on to metformin. This update allowed inclusion of a new drug class (glucagon-like peptide-1 [GLP-1] analogues), a new time point (24-weeks) and covariate analysis. Methods:The systematic review identified randomised controlled trials involving patients with type-2 diabetes mellitus (T2DM) inadequately controlled on metformin. Comparators included dipeptidyl peptidase-4 inhibitors (DPP-4i), thiazolidinediones (TZDs), GLP-1s, sulfonylureas (SUs) and dapagliflozin. Bayesian NMA was conducted at 24-and 52-weeks for mean change in HbA1c, systolic blood pressure (SBP), weight, and proportion of patients experiencing hypoglycaemia. Results:The systematic review identified 2247 articles, of which 16were eligible for inclusion. Combined with 19 studies frompre-2011 analysis, a total of 19 and 8 studies were included in the 24-week and 52-week NMA, respectively. There were no significant differences in HbA1c or SBP between dapagliflozin and other classes, including GLP-1s, at either time point. Significant results were seen for weight loss by 24-weeks for dapagliflozin versusDPP-4i (-2.24 kg [95% CI -3.25,-1.24]) and TZDs (-4.65 kg [-5.89,-3.45]), and at 52-weeks versus SUs, DPP-4i and TZDs. Dapagliflozin also resulted in significantly lower hypoglycaemia risk versus SU (OR: 0.05 [0.01,0.19]) over 52-weeks. Conclusions:This NMA update supports previous findings that effects on HbA1c are similar between drug classes and that dapagliflozin plus metformin offers superior weight control for T2DM patients compared with many other agents. The wider evidence base compared to previous analysis increases the confidence in the results.

show abstract

Efficacy and tolerability of vildagliptin as add‐on therapy to metformin in Chinese patients with type 2 diabetes mellitus

Abstract: Vildagliptin as add-on therapy to metformin improved glycaemic control and was well tolerated in Chinese patients who were inadequately controlled by metformin only.

Cited by 72 publications

References 28 publications

Effectiveness, Safety and Tolerability of Vildagliptin with or without Metformin in Bangladeshi Patients with Type 2 Diabetes Mellitus: Results from Real-Life Observational Study

Effectiveness, Safety and Tolerability of Vildagliptin with or without Metformin in Bangladeshi Patients with Type 2 Diabetes Mellitus: Results from Real-Life Observational Study

Comparison of efficacy and safety of metformin and vildagliptin versus metformin and glimepiride in patients of Type 2 diabetes mellitus

Systematic Review and Network Meta-analysis to Compare Dapagliflozin with other Diabetes Medications in Combination with Metformin for Adults with Type 2 Diabetes

Contact Info

Product

Resources

About